Copyright investors
The Relative Strength (RS) Rating for Vera Therapeutics (VERA) moved into a new percentile Tuesday, as it got a lift from 64 to 72. IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database. History reveals that the top-performing stocks often have an 80 or higher RS Rating as they begin their biggest runs. See if Vera Therapeutics can continue to rebound and clear that threshold. Vera Therapeutics broke out earlier, but is now trading approximately 5% below the prior 31.80 entry from a cup with handle. If a stock you're tracking clears a buy point then retreats 7% or more below the original entry price, it's considered a failed base. Wait for the stock to set up and breakout from a new chart pattern and buy point. Also understand that the latest pattern is a later-stage base, which makes it riskier to establish a new position or add shares to an existing one. The company reported 0% EPS growth in its most recent report, while sales growth came in at 0%. The company is expected to report its latest performance numbers on or around Nov. 5. Vera Therapeutics earns the No. 347 rank among its peers in the Medical-Biomed/Biotech industry group. argenx ADR (ARGX), Aurinia Pharmaceuticals (AUPH) and Halozyme Therapeutics (HALO) are among the top 5 highly rated stocks within the group. This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
